InvestorsHub Logo
Post# of 253566
Next 10
Followers 839
Posts 120698
Boards Moderated 13
Alias Born 09/05/2002

Re: dewophile post# 252379

Thursday, 08/01/2024 12:46:28 PM

Thursday, August 01, 2024 12:46:28 PM

Post# of 253566
MRNA—(-21%)—reports 2Q24 results—cuts 2024 sales guidance:

https://finance.yahoo.com/news/moderna-reports-second-quarter-2024-103000708.html

The Company revises its 2024 expected net product sales to $3.0 to $3.5 billion from its respiratory franchise. …The update in product sales is driven by three primary factors: very low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.

The 2024 sales guidance given three months ago was $4B, so the new guidance is a reduction of $500M-$1.0B.

The third reason for the guidance cut cited above — “an increasingly competitive environment for respiratory vaccines in the U.S.” — is not well stated. The competition per se for respiratory vaccines in the US has not increased (the three players in RSV vaccines remain GSK, PFE, and MRNA); however, the CDC reduced the addressable US market for RSV vaccines by omitting adults age 60-74 without increased risk factors for severe disease, while also postponing any recommendation about booster shots (https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-06-26-28/12-RSV-Adult-Melgar-508.pdf ).

The first two reasons cited above for the guidance cut — “very low EU sales in 2024” and “potential revenue deferrals for certain international sales into 2025” are essentially the same issue: PFE/BNTX have locked up most of the European market for COVID vaccines in 2024-2025.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.